The road to therapy for myeloid sarcoma: navigating the complexities of subclonal MAPK / ERK mutations and clonal evolution

The recent seminal work by Nann and colleagues, ‘Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis’ provides a crucial genomic framework for this rare and aggressive malignancy [1]. By rigorously demonstrating the high prevalence of KRAS, NRAS, and PTPN11 mutations and linking a subset of cases to clonal hematopoiesis (CH), the authors have rightly shifted the paradigm for understanding myeloid sarcoma (MS) pathogenesis. While these findings are undoubtedly significant, a critical appraisal reveals several profound biological and clinical challenges that must be addressed to translate this genetic atlas into therapeutic progress. First, the functional and clinical implications of subclonal MAPK/ERK mutations demand a more nuanced interpretation than presented. While the high frequency (44%) is striking, the subclonal nature of many of these mutations suggests they may not be the universal founding oncogenic event. A critical, unanswered question is whether MAPK/ERK activation is a bona fide driver of extramedullary tropism or merely a passenger event that confers a proliferative advantage within a permissive niche. The study's data, while correlative, cannot distinguish between these possibilities. If these mutations are indeed key to tissue invasion, why do we not observe universal, clonal dominance? This heterogeneity poses a direct threat to the efficacy of targeted therapies. MEK or ERK inhibitor monotherapy, as successfully deployed in other rat sarcoma (RAS)-pathway-driven cancers [2], would likely select for the outgrowth of pre-existing, MAPK-wild-type subclones, leading to rapid clinical resistance. Therefore, the therapeutic strategy for MS may need to pivot towards rational combinations that target a more fundamental dependency of the MS-initiating cell, such as BCL-2 inhibition [3], concurrently with MAPK pathway suppression to prevent escape. Second, the provocative association with CH requires stringent validation and mechanistic exploration. The authors propose a compelling ‘two-hit’ model where CH provides the initial pre-leukemic clone, with subsequent MAPK/ERK mutation triggering overt MS. However, the phylogenetic relationship between the CH clone and the dominant MS clone remains largely inferential from the data shown. Definitive proof requires single-cell DNA sequencing of MS lesions and paired bone marrow to reconstruct the precise evolutionary trajectory. Furthermore, the immunological consequences of this trajectory are entirely unexplored. CH is known to create a pro-inflammatory bone marrow milieu and can remodel the immune system, potentially fostering a permissive environment for secondary oncogenic events [4]. It is plausible that CH-derived MS represents a distinct immunobiological entity compared to de novo MS. Characterizing the tumor microenvironment (TME) of CH-associated versus non-CH-associated MS using high-parameter spatial proteomics or transcriptomics is an essential next step. This could reveal whether the CH origin predisposes to an immune-cold TME, which would have significant implications for the potential of immunotherapy [3]. Finally, the study inadvertently highlights a critical gap in our understanding of the MS stromal niche. The data elegantly characterize the tumor cells but leave the supportive stroma as a ‘black box’. The MAPK/ERK pathway is a potent regulator of cytokine and chemokine secretion [3, 4]. It is therefore conceivable that mutant MS cells actively remodel their local extramedullary niche into a self-reinforcing, pro-survival sanctuary. The reported JAK2 V617F case further underscores the potential role of aberrant cytokine signaling. Does mutant RAS signaling in MS cells upregulate IL-6, GM-CSF, or other factors that re-educate local macrophages and fibroblasts into pro-tumorigenic allies? Co-culture models of MS cell lines with stromal components could functionally test this hypothesis and identify potential stromal targets for therapy [4]. In conclusion, Nann et al have delivered a foundational study that redefines MS as a disease of RASopathy and clonal evolution [1]. The path forward now lies in moving beyond correlation to causation. This necessitates functional in vivo modelling to test the role of these mutations in extramedullary homing, deep phylogenetic tracking to resolve the CH-MS continuum and a comprehensive dissection of the dynamic interplay between MS cells and their TME. Addressing these substantive challenges will be paramount in determining whether targeting the MAPK/ERK pathway, perhaps within a carefully timed window or in rational combination, can finally alter the dismal prognosis of this disease. We received fund from The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Biomechanical research on cartilage transplantation based on the theory of ‘equal emphasis on muscle and bone’, 2023ZYQJ02. DY: conceptualization, methodology, writing – original draft preparation, supervision. JY: validation, resources, writing – review and editing. GW: project administration, funding acquisition, supervision. All authors have read and agreed to the final version of the manuscript. No data were generated or analyzed for or in support of this paper.